Entera Bio Ltd

-0.05 (-1.32%)
Earnings Announcements

Entera Bio Reports Q1 Revenue Of $157,000

Published: 05/20/2021 12:34 GMT
Entera Bio Ltd (ENTX) - Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates.
Q1 Revenue $157,000.
Phase 2 Eb613 Clinical Trial in Osteoporosis Achieves 3-month Primary Endpoint; Final Data Including Bmd Expected Q2 2021.
Expected Cash Runway Into Q2 of 2022.
Q1 Loss per Share $0.43.
Revenue is expected to be $0.17 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $0.19 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.